Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm Metastasis × tucatinib × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 Neoplasms 3 Meningeal Neoplasms 3 Colorectal Neoplasms 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Rectal Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Colonic Neoplasms 2 Brain Neoplasms 2 Pathologic Complete Response 1 Neoplasm Metastasis 1 Metastatic Breast Cancer With a Isolated Brain Progression 1 Meningeal Carcinomatosis 1 Hemangiosarcoma 1 HER2-positive Gastric Cancer 1 HER2-positive Breast Cancer 1 Gallbladder Neoplasms 1 Esophageal Neoplasms 1 Cholangiocarcinoma 1 Adenocarcinoma Of Esophagus 1 Adenocarcinoma 1

Interventions

Oxaliplatin 58 Capecitabine 56 Fluorouracil 53 Bevacizumab 50 Leucovorin 46 Paclitaxel 45 Gemcitabine 45 Carboplatin 37 Nivolumab 36 Irinotecan 34 Docetaxel 33 pembrolizumab 32 Cisplatin 31 Cetuximab 30 Radiosurgery 22 Trastuzumab 21 Cyclophosphamide 20 Sunitinib 19 Panitumumab 19 Radiotherapy 18 Doxorubicin 18 Interleukin-2 16 Pemetrexed 15 Fulvestrant 15 Everolimus 15 Drug Therapy 15 atezolizumab 14 Ipilimumab 14 Albumin-Bound Paclitaxel 14 Sorafenib 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07193394 2026-02-23

H3RAKLES

Institut Curie

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡